Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Not every patient with multiple sclerosis should be treated at time of diagnosis.

× No keyword cloud information.

10 in total

1. Optic Neuritis: The Role of Disease-modifying Therapy in This Clinically Isolated Syndrome.

Authors: Fiona Costello
Journal: Curr Treat Options Neurol Date: 2007-01 Impact factor: 3.598

2. Estimating Time to Event From Longitudinal Categorical Data: An Analysis of Multiple Sclerosis Progression.

Authors: Micha Mandel; Susan A Gauthier; Charles R G Guttmann; Howard L Weiner; Rebecca A Betensky
Journal: J Am Stat Assoc Date: 2007-12 Impact factor: 5.033

3. Proteomic strategies in multiple sclerosis and its animal models.

Authors: Stella Elkabes; Hong Li
Journal: Proteomics Clin Appl Date: 2007-10-16 Impact factor: 3.494

4. Multiple sclerosis risk after optic neuritis: final optic neuritis treatment trial follow-up.

Authors:
Journal: Arch Neurol Date: 2008-06

Review 5. Treatment strategies for multiple sclerosis: When to start, when to change, when to stop?

Authors: Alberto Gajofatto; Maria Donata Benedetti
Journal: World J Clin Cases Date: 2015-07-16 Impact factor: 1.337

6. Early prediction of the long term evolution of multiple sclerosis: the Bayesian Risk Estimate for Multiple Sclerosis (BREMS) score.

Authors: Roberto Bergamaschi; Silvana Quaglini; Maria Trojano; Maria Pia Amato; Eleonora Tavazzi; Damiano Paolicelli; Valentina Zipoli; Alfredo Romani; Aurora Fuiani; Emilio Portaccio; Carlo Berzuini; Cristina Montomoli; Stefano Bastianello; Vittorio Cosi
Journal: J Neurol Neurosurg Psychiatry Date: 2007-01-12 Impact factor: 10.154

Not every patient with multiple sclerosis should be treated at time of diagnosis.

1. Optic Neuritis: The Role of Disease-modifying Therapy in This Clinically Isolated Syndrome.

2. Estimating Time to Event From Longitudinal Categorical Data: An Analysis of Multiple Sclerosis Progression.

3. Proteomic strategies in multiple sclerosis and its animal models.

4. Multiple sclerosis risk after optic neuritis: final optic neuritis treatment trial follow-up.

Review 5. Treatment strategies for multiple sclerosis: When to start, when to change, when to stop?

6. Early prediction of the long term evolution of multiple sclerosis: the Bayesian Risk Estimate for Multiple Sclerosis (BREMS) score.

7. Risk-benefit considerations in the treatment of relapsing-remitting multiple sclerosis.

8. Conversion from radiologically isolated syndrome to multiple sclerosis.

Review 9. Multiple sclerosis therapy: an update on recently finished trials.

10. Treatment selection and experience in multiple sclerosis: survey of neurologists.